
Silence Therapeutics (SLN) Stock Forecast & Price Target
Silence Therapeutics (SLN) Analyst Ratings
Bulls say
Silence Therapeutics PLC demonstrates a strong portfolio with validated data indicating robust target engagement through increased levels of hepcidin and ferritin, reflecting positive trends in addressing iron deficiency without dose-limiting toxicities. The company appears to be on a clear trajectory for sustained value creation, bolstered by anticipated clinical, business development, and platform milestones, which are expected to drive significant upside. Furthermore, the presence of multiple near- and mid-term catalysts across various therapeutic areas enhances the potential for meaningful advancements and value appreciation.
Bears say
Silence Therapeutics PLC, while engaged in innovative siRNA drug development, showcases a lack of diversified revenue streams and limited commercialization success, which may impact its financial sustainability. The company’s reliance on its pipeline for future growth, particularly in niche therapeutic areas, raises concerns about potential market competition and regulatory hurdles. Furthermore, the ongoing need for significant capital investment in research and development without guaranteed returns could lead to heightened financial risk and uncertainty surrounding the company’s overall valuation.
This aggregate rating is based on analysts' research of Silence Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Silence Therapeutics (SLN) Analyst Forecast & Price Prediction
Start investing in Silence Therapeutics (SLN)
Order type
Buy in
Order amount
Est. shares
0 shares